IL237672B - Drug-protein conjugates - Google Patents
Drug-protein conjugatesInfo
- Publication number
- IL237672B IL237672B IL237672A IL23767215A IL237672B IL 237672 B IL237672 B IL 237672B IL 237672 A IL237672 A IL 237672A IL 23767215 A IL23767215 A IL 23767215A IL 237672 B IL237672 B IL 237672B
- Authority
- IL
- Israel
- Prior art keywords
- drug
- protein conjugates
- conjugates
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717710P | 2012-10-24 | 2012-10-24 | |
| US201261717743P | 2012-10-24 | 2012-10-24 | |
| US201361811285P | 2013-04-12 | 2013-04-12 | |
| PCT/GB2013/051593 WO2013190292A2 (en) | 2012-06-19 | 2013-06-19 | Novel process for preparation of antibody conjugates and novel antibody conjugates |
| PCT/GB2013/052661 WO2014064423A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL237672A0 IL237672A0 (en) | 2015-04-30 |
| IL237672B true IL237672B (en) | 2018-02-28 |
Family
ID=50544085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237672A IL237672B (en) | 2012-10-24 | 2015-03-11 | Drug-protein conjugates |
Country Status (18)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015156888A (ru) | 2013-06-04 | 2017-07-14 | Сайтомкс Терапьютикс, Инк. | Композиции и методы конъюгирования активируемых антител |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| EP3145552B1 (en) * | 2014-05-23 | 2020-03-04 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
| AU2015274506C1 (en) * | 2014-06-12 | 2022-10-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Homogenous antibody drug conjugates via enzymatic methods |
| WO2016059377A1 (en) * | 2014-10-14 | 2016-04-21 | Polytherics Limited | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
| BR112017005760A2 (pt) * | 2014-10-24 | 2017-12-12 | Polytherics Ltd | conjugados e reagentes de conjugação |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| JP6486316B2 (ja) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法 |
| JP2019501131A (ja) | 2015-12-04 | 2019-01-17 | シアトル ジェネティックス， インコーポレイテッド | 四級化チューブリシン化合物の複合体 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| KR20180134351A (ko) | 2016-03-25 | 2018-12-18 | 시애틀 지네틱스, 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| EP3442595A1 (en) * | 2016-04-14 | 2019-02-20 | Polytherics Limited | Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring |
| GB201608936D0 (en) * | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| WO2017212250A1 (en) * | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| GB201820864D0 (en) * | 2018-12-20 | 2019-02-06 | J A Kemp | Antibody-drug conjugates |
| EP4117729A4 (en) * | 2020-04-15 | 2023-11-15 | Shenzhen Enduring Biotech, Ltd. | ANTIBODY-DRUG CONJUGATE |
| JP2024510760A (ja) * | 2021-03-19 | 2024-03-11 | シェンチェン・エンデュアリング・バイオテック・リミテッド | Ｃｄ３およびｃｄ１９に二重特異性を有するｐｅｇ化ｔ細胞エンゲージャー |
| WO2023141855A1 (en) * | 2022-01-27 | 2023-08-03 | Glyco-Therapy Biotechnology Co., Ltd. | Protein conjugates with multiple payloads and methods for making the same |
| TW202444426A (zh) * | 2023-03-29 | 2024-11-16 | 美商艾克塞里克斯公司 | Amhrii抗體-藥物結合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2557389T3 (es) * | 2003-11-06 | 2016-01-25 | Seattle Genetics, Inc. | Compuestos de monometilvalina conjugados con anticuerpos |
| JP5290756B2 (ja) * | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
| SI2211904T1 (sl) * | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| EP2842575B1 (en) | 2008-03-18 | 2017-09-27 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| MX2010011808A (es) * | 2008-04-30 | 2011-03-04 | Immunogen Inc | Conjugados potentes y enlazadores hidrofilicos. |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| NZ595574A (en) * | 2009-04-01 | 2013-11-29 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| AR078471A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| JP6384963B2 (ja) * | 2012-04-25 | 2018-09-05 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 勾配コイルを置くためのシステム及び方法 |
| RU2015101333A (ru) * | 2012-06-19 | 2016-08-10 | Политерикс Лимитед | Новый способ получения конъюгатов антител и новые конъюгаты антител |
-
2013
- 2013-10-11 US US14/437,537 patent/US20150290342A1/en not_active Abandoned
- 2013-10-11 BR BR112015008376A patent/BR112015008376A2/pt not_active Application Discontinuation
- 2013-10-11 SG SG11201501618WA patent/SG11201501618WA/en unknown
- 2013-10-11 CN CN201380055880.6A patent/CN104870021B/zh active Active
- 2013-10-11 MY MYPI2015701285A patent/MY169147A/en unknown
- 2013-10-11 MX MX2015005122A patent/MX2015005122A/es unknown
- 2013-10-11 EP EP13786530.9A patent/EP2911700B1/en active Active
- 2013-10-11 EP EP16203350.0A patent/EP3159013A1/en not_active Withdrawn
- 2013-10-11 RU RU2015119561A patent/RU2015119561A/ru unknown
- 2013-10-11 JP JP2015538560A patent/JP6328648B2/ja active Active
- 2013-10-11 AU AU2013336409A patent/AU2013336409B2/en active Active
- 2013-10-11 KR KR1020157011427A patent/KR102209395B1/ko active Active
- 2013-10-11 DK DK13786530.9T patent/DK2911700T5/en active
- 2013-10-11 CA CA2884299A patent/CA2884299A1/en not_active Abandoned
- 2013-10-11 WO PCT/GB2013/052661 patent/WO2014064423A1/en active Application Filing
- 2013-10-11 ES ES13786530.9T patent/ES2623209T3/es active Active
- 2013-10-11 IN IN2349DEN2015 patent/IN2015DN02349A/en unknown
-
2015
- 2015-03-10 ZA ZA2015/01642A patent/ZA201501642B/en unknown
- 2015-03-11 IL IL237672A patent/IL237672B/en active IP Right Grant
-
2021
- 2021-09-17 US US17/477,565 patent/US20220062436A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2623209T3 (es) | 2017-07-10 |
| DK2911700T3 (en) | 2017-05-15 |
| BR112015008376A2 (pt) | 2017-09-26 |
| EP2911700A1 (en) | 2015-09-02 |
| DK2911700T5 (en) | 2017-05-22 |
| KR102209395B1 (ko) | 2021-01-28 |
| JP6328648B2 (ja) | 2018-05-23 |
| IN2015DN02349A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-08-28 |
| IL237672A0 (en) | 2015-04-30 |
| EP2911700B1 (en) | 2017-02-08 |
| CN104870021B (zh) | 2018-03-13 |
| SG11201501618WA (en) | 2015-04-29 |
| HK1208187A1 (en) | 2016-02-26 |
| JP2015533847A (ja) | 2015-11-26 |
| ZA201501642B (en) | 2016-01-27 |
| US20220062436A1 (en) | 2022-03-03 |
| WO2014064423A1 (en) | 2014-05-01 |
| CA2884299A1 (en) | 2014-05-01 |
| AU2013336409A1 (en) | 2015-04-02 |
| RU2015119561A (ru) | 2016-12-20 |
| EP3159013A1 (en) | 2017-04-26 |
| US20150290342A1 (en) | 2015-10-15 |
| AU2013336409B2 (en) | 2017-08-03 |
| CN104870021A (zh) | 2015-08-26 |
| MY169147A (en) | 2019-02-18 |
| KR20150103656A (ko) | 2015-09-11 |
| MX2015005122A (es) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
| IL263973B (en) | Protein-polymer-drug conjugates | |
| ZA201501996B (en) | Drug-protein conjugates | |
| IL237672B (en) | Drug-protein conjugates | |
| ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
| ZA201502267B (en) | Pyrrolobenzodiazepine-anti-her2 antibody conjugates | |
| PL2906253T3 (pl) | Koniugaty pirolobenzodiazepina-przeciwciało anty-psma | |
| RS56520B1 (sr) | Pirolobenzodiazepin-anti-cd22 konjugati antitela | |
| IL228404A0 (en) | Antibody-drug captures | |
| PT2920167T (pt) | Compostos de hidrazinil-indol e conjugados | |
| PL2717917T3 (pl) | Koniugaty p97 - przeciwciało | |
| ZA201408914B (en) | Conjugation reagents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |